Breaking News
Investing Pro 0
🚨 Our Pro Data Reveals the True Winner of Earnings Season Access Data

EU regulator backs mRNA vaccine booster for people with weak immunity

Stock Markets Oct 04, 2021 12:16PM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
2/2 © Reuters. FILE PHOTO: Health workers speak with Mauricette, a 78-year-old French woman, after she received the first dose of the Pfizer-BioNTech coronavirus disease (COVID-19) vaccine in the country, at the Rene-Muret hospital in Sevran, on the outskirts of Paris, 2/2
 
PFE
+1.40%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
MRNA
-2.66%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 

By Ludwig Burger and Yadarisa Shabong

(Reuters) -The European Union's drugs regulator said on Monday people with weakened immune systems should get a third dose of a COVID-19 vaccine from Pfizer-BioNTech or Moderna (NASDAQ:MRNA), but left it to member states to decide if the wider population should have a booster.

The long-awaited guidance comes after several EU member states pre-empted the European Medicines Agency's (EMA) opinion and launched their own booster campaigns, although they vary widely over who is eligible.

The EU joins the United States, Britain and Israel where regulators have approved the use of Pfizer-BioNTech boosters, although there is no consensus among scientists about how broadly they should be rolled out. Israel is the outlier, deploying them across the whole population.

The EMA said people with a severely weakened immune system should be given a third dose of the Pfizer-BioNTech and Moderna vaccines - both based on so-called mRNA technology - at least 28 days after their second one.

Many treatments for cancer patients or for people with organ transplants suppress the immune system, making them particularly vulnerable to a coronavirus infection with reduced help offered from vaccines.

Results from Italian studies released on Monday showed COVID-19 vaccines are less effective on people with weakened immune systems.

The EMA also said a booster shot of the Pfizer-BioNTech vaccine could be considered for adults with normal immune systems around six months after the second dose, but added that was up to individual countries.

Governments are under pressure to revive their ailing economies, fight the more infectious Delta variant, and avoid further lockdowns this winter.

The EMA's ruling comes after the EU's infectious diseases centre warned last week the region's coverage of vaccines was still too low and there was a risk of a significant surge in cases, hospitalisations and deaths over the next six weeks.

MORE DATA

Marc Van Ranst, virologist at the University of Leuven in Belgium said decision on boosters was expected and would "legitimise the choices that some governments already made" in Europe.

He added the EMA’s broad go-ahead could lead to a further fragmentation of national decisions on the use of boosters, but more data was needed for the regulator to justify a more specific verdict.

Antonella Viola, professor of immunology at Italy's University of Padua, said the risk of heart inflammation from the mRNA vaccines, albeit rare, needed to be taken into account and the benefit of a booster for younger adults was questionable.

The World Health Organization has criticised rich nations for hoarding COVID-19 vaccines for booster campaigns for larger population groups while poorer countries are struggling to rollout even first doses.

Allowing EU countries to decide broader use of a booster is consistent with the EMA's earlier decisions in the pandemic - for instance it largely left it up to member states to decide whether to restrict vaccines in the face of potential side effects.

The EMA said it was hoping to see more data to underpin recommendation updates.

Pfizer (NYSE:PFE) and BioNTech presented data in their filings for their booster that showed levels of virus-fighting antibodies in the blood of vaccinated people wane over time and that a third shot was shown to cause a fresh surge in antibodies.

Researchers say immune cells, another important factor in immunisation, might confer longer-lasting protection against severe disease but their presence in the blood is more difficult to measure and more research is needed.

The University of Padua's Viola said the young and healthy, in particular, should be not get a repeat shot.

"The vaccines we have used protect everyone from severe disease with very high efficacy," she added.

The EMA said on Sept. 6 it had begun evaluating data submitted by Pfizer and BioNTech for a booster dose in people with a functioning immune system, with infections among vaccinated people adding urgency to its review.

It also started evaluating last week the merits of a booster dose of Moderna's COVID-19 vaccine.

EU regulator backs mRNA vaccine booster for people with weak immunity
 

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Comments (1)
Felipe Daniel
Felipe Daniel Oct 04, 2021 1:41PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Why are governments ignoring natural immunity? Proven to be more lasting and stronger than that provided by vaccine and without the side effects? Is it maybe because regulators and politicians are owned by pharmaceutical lobby?
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email